ZAVESCA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZAVESCA (ZAVESCA).
Inhibits glucosylceramide synthase, reducing synthesis of glycosphingolipids including glucocerebroside.
| Metabolism | Primarily metabolized by CYP3A4; minor involvement of CYP2D6 and CYP2C19. |
| Excretion | Renal (predominantly): 70% unchanged, fecal: 20% as metabolites, biliary: minor. |
| Half-life | 6-7 hours; in patients with hepatic impairment, up to 12-15 hours. |
| Protein binding | 60% bound, primarily to albumin. |
| Volume of Distribution | 2-5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: ~97% (highly absorbed), with food decreasing rate but not extent. |
| Onset of Action | Oral: 2-4 weeks for symptomatic improvement in Gaucher disease; 6-12 months for neurological stabilization in Niemann-Pick type C. |
| Duration of Action | 12 hours (dosing interval); clinical effect persists with continued therapy. |
100 mg orally three times daily.
| Dosage form | CAPSULE |
| Renal impairment | For GFR 50-70 mL/min/1.73m2: 100 mg twice daily; for GFR 30-50: 100 mg once daily; for GFR <30: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 100 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight-based dosing: <47 kg: 100 mg three times daily; ≥47 kg: 200 mg three times daily (adult dose). |
| Geriatric use | No specific adjustment; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZAVESCA (ZAVESCA).
| Breastfeeding | It is not known whether miglustat is excreted in human milk. In lactating rats, miglustat was excreted in milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 6 weeks after the last dose. M/P ratio is unknown. |
| Teratogenic Risk | ZAVESCA (miglustat) is classified as FDA Pregnancy Category C. In animal studies, miglustat caused embryofetal toxicity including reduced fetal weight, increased resorptions, and skeletal variations at maternal toxic doses. There are no adequate and well-controlled studies in pregnant women. Potential fetal risk cannot be ruled out, especially during first trimester organogenesis. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to miglustat or any component"]
| Precautions | ["Peripheral neuropathy","Tremor","Gastrointestinal disturbances","Decreased fertility in males","Monitor for tremors and neuropathy"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth and development via ultrasound. Assess for signs of oligohydramnios if used in second/third trimester. Monitor maternal neurological symptoms (tremor, paresthesia) and gastrointestinal tolerability. Periodic liver function tests and blood counts are recommended. |
| Fertility Effects | In animal studies, miglustat did not impair fertility in male or female rats. There are no human data on fertility effects. Potential effects on human fertility are unknown. |